Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects

被引：0
|
作者：
Landovitz, R.
Faetkenhauer, G.
Hoffmann, C.
Horst, H.
Strizki, J.
Whitcomb, J.
Gheyas, F.
Knepp, D.
Greaves, W.
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Univ Cologne, Dept Internal Med, D-5000 Cologne 41, Germany
[3] Hosp St George, Dept Internal Med, Hamburg, Germany
[4] Univ Kiel, Dept Internal Med, D-24098 Kiel, Germany
[5] Monogram Biosci Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211)
    Crawford, Keith W.
    Li, Chonghua
    Keung, Anther
    Su, Zhaohui
    Hughes, Michael D.
    Greaves, Wayne
    Kuritzkes, Daniel
    Gulick, Roy
    Flexner, Charles
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (05) : 598 - 605
  • [2] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [3] Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
    Klibanov, Olga M.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 845 - 859
  • [4] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2008, 22 (16) : 2212 - 2214
  • [5] Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naive Subjects
    Lalezari, Jacob
    Gathe, Joseph
    Brinson, Cynthia
    Thompson, Melanie
    Cohen, Calvin
    Dejesus, Edwin
    Galindez, Jorge
    Ernst, Jerome A.
    Martin, David E.
    Palleja, Sandra M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (02) : 118 - 125
  • [6] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
    Kuemmerle, Tim
    Lehmann, Clara
    Hartmann, Pia
    Wyen, Christoph
    Faetkenheuer, Gerd
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785
  • [7] Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults
    Schuermann, Dirk
    Faetkenheuer, Gerd
    Reynes, Jacques
    Michelet, Christian
    Raffi, Francois
    van Lier, Jan
    Caceres, Maria
    Keung, Anther
    Sansone-Parsons, Angela
    Dunkle, Lisa M.
    Hoffmann, Christian
    AIDS, 2007, 21 (10) : 1293 - 1299
  • [8] Characterization of Emergent HIV Resistance in Treatment-Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
    McNicholas, Paul
    Wei, Yi
    Whitcomb, Jeannette
    Greaves, Wayne
    Black, Todd A.
    Tremblay, Cecile L.
    Strizki, Julie M.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (10): : 1470 - 1480
  • [9] Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected Treatment-Experienced Patients
    Wilkin, Timothy J.
    Su, Zhaohui
    Krambrink, Amy
    Long, Jianmin
    Greaves, Wayne
    Gross, Robert
    Hughes, Michael D.
    Flexner, Charles
    Skolnik, Paul R.
    Coakley, Eoin
    Godfrey, Catherine
    Hirsch, Martin
    Kuritzkes, Daniel R.
    Gulick, Roy M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (05) : 470 - 476
  • [10] Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naive Patients
    Marier, Jean-Francois
    Trinh, MyMy
    Leng Hong Pheng
    Palleja, Sandra M.
    Martin, David E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (06) : 2768 - 2774
12345